Nuvectis Pharma, Inc. (NASDAQ:NVCT) CEO Ron Bentsur Acquires 4,500 Shares

Nuvectis Pharma, Inc. (NASDAQ:NVCT - Get Free Report) CEO Ron Bentsur acquired 4,500 shares of the firm's stock in a transaction dated Tuesday, December 24th. The stock was bought at an average price of $4.65 per share, for a total transaction of $20,925.00. Following the acquisition, the chief executive officer now owns 3,270,924 shares of the company's stock, valued at approximately $15,209,796.60. This trade represents a 0.14 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link.

Ron Bentsur also recently made the following trade(s):

• On Friday, November 15th, Ron Bentsur bought 20,000 shares of Nuvectis Pharma stock. The stock was purchased at an average price of $4.92 per share, for a total transaction of $98,400.00.

Nuvectis Pharma Stock Performance

NASDAQ:NVCT traded up $0.37 during midday trading on Thursday, reaching $5.02. 102,047 shares of the stock traded hands, compared to its average volume of 116,726. The stock has a market capitalization of $96.99 million, a P/E ratio of -4.33 and a beta of 0.20. The company has a fifty day moving average of $6.29 and a 200 day moving average of $6.47. Nuvectis Pharma, Inc. has a 12 month low of $4.44 and a 12 month high of $12.10.

Nuvectis Pharma (NASDAQ:NVCT - Get Free Report) last released its quarterly earnings data on Tuesday, November 5th. The company reported ($0.24) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.25) by $0.01. During the same quarter in the previous year, the firm posted ($0.37) earnings per share. On average, analysts predict that Nuvectis Pharma, Inc. will post -1.01 EPS for the current fiscal year.

Institutional Investors Weigh In On Nuvectis Pharma

Large investors have recently made changes to their positions in the business. Point72 Asia Singapore Pte. Ltd. purchased a new stake in Nuvectis Pharma in the second quarter worth $58,000. Nations Financial Group Inc. IA ADV purchased a new stake in shares of Nuvectis Pharma in the 3rd quarter worth about $63,000. GSA Capital Partners LLP boosted its stake in shares of Nuvectis Pharma by 3.7% during the 3rd quarter. GSA Capital Partners LLP now owns 50,129 shares of the company's stock valued at $315,000 after purchasing an additional 1,790 shares in the last quarter. Iridian Asset Management LLC CT purchased a new position in shares of Nuvectis Pharma during the third quarter valued at about $348,000. Finally, Renaissance Technologies LLC raised its stake in Nuvectis Pharma by 20.7% in the second quarter. Renaissance Technologies LLC now owns 74,500 shares of the company's stock worth $472,000 after buying an additional 12,800 shares in the last quarter. 96.77% of the stock is currently owned by institutional investors.

About Nuvectis Pharma

Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.